ES2899978T3 - Sistema de expresión potenciada mediada por ICP0 - Google Patents

Sistema de expresión potenciada mediada por ICP0 Download PDF

Info

Publication number
ES2899978T3
ES2899978T3 ES16724820T ES16724820T ES2899978T3 ES 2899978 T3 ES2899978 T3 ES 2899978T3 ES 16724820 T ES16724820 T ES 16724820T ES 16724820 T ES16724820 T ES 16724820T ES 2899978 T3 ES2899978 T3 ES 2899978T3
Authority
ES
Spain
Prior art keywords
icpo
cell
cells
virus
recombinant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16724820T
Other languages
English (en)
Spanish (es)
Inventor
Simon Delagrave
Charchang Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANOFI PASTEUR Inc
Original Assignee
SANOFI PASTEUR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANOFI PASTEUR Inc filed Critical SANOFI PASTEUR Inc
Application granted granted Critical
Publication of ES2899978T3 publication Critical patent/ES2899978T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES16724820T 2015-05-13 2016-05-12 Sistema de expresión potenciada mediada por ICP0 Active ES2899978T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562161194P 2015-05-13 2015-05-13
PCT/US2016/032082 WO2016183312A1 (en) 2015-05-13 2016-05-12 Icp0-mediated enhanced expression system

Publications (1)

Publication Number Publication Date
ES2899978T3 true ES2899978T3 (es) 2022-03-15

Family

ID=56072466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16724820T Active ES2899978T3 (es) 2015-05-13 2016-05-12 Sistema de expresión potenciada mediada por ICP0

Country Status (5)

Country Link
US (2) US10208292B2 (de)
EP (1) EP3294875B8 (de)
CA (1) CA2985649A1 (de)
ES (1) ES2899978T3 (de)
WO (1) WO2016183312A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985649A1 (en) 2015-05-13 2016-11-17 Sanofi Pasteur Biologics, Llc Icp0-mediated enhanced expression system
WO2018226638A1 (en) * 2017-06-05 2018-12-13 The Brigham And Women's Hospital, Inc. Vero cell lines stably expressing hsv icp0 protein
WO2020006486A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001301A1 (en) * 1991-07-05 1993-01-21 The Penn State Research Foundation Mutant antiviral regulatory proteins
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US6261552B1 (en) * 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US9365832B2 (en) * 2012-01-09 2016-06-14 Sanofi Pasteur Biologics, Llc Purification of herpes virus
JP6726824B2 (ja) * 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
CA2985649A1 (en) 2015-05-13 2016-11-17 Sanofi Pasteur Biologics, Llc Icp0-mediated enhanced expression system
WO2018226638A1 (en) * 2017-06-05 2018-12-13 The Brigham And Women's Hospital, Inc. Vero cell lines stably expressing hsv icp0 protein

Also Published As

Publication number Publication date
US11286465B2 (en) 2022-03-29
EP3294875A1 (de) 2018-03-21
CA2985649A1 (en) 2016-11-17
US10208292B2 (en) 2019-02-19
WO2016183312A1 (en) 2016-11-17
EP3294875B1 (de) 2021-09-15
EP3294875B8 (de) 2021-10-20
US20190194626A1 (en) 2019-06-27
US20180119111A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
Fan et al. Swine TRIM21 restricts FMDV infection via an intracellular neutralization mechanism
US10806761B2 (en) Oncolytic HSV1 vector and methods of use
US12098380B2 (en) Vero cell lines stably expressing HSV ICP0 protein
Schneeweiss et al. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII
US11286465B2 (en) ICP0-mediated enhanced expression system
CN116212022A (zh) 一种芳香烃受体基因AhR作为治疗靶点在制备抗HSV-1病毒药物中的应用
CN114292849A (zh) Yap/taz蛋白作为靶分子在制备抗甲型流感病毒药物中的应用
EA009782B1 (ru) Пептид, происходящий из вируса гепатита с
Lynch et al. Modified vaccinia virus Ankara can activate NF-κB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication
US9474796B2 (en) Crimean-Congo hemorrhagic fever virus vaccine
Meier et al. Homotypic and heterotypic exclusion of vesicular stomatitis virus replication by high levels of recombinant polymerase protein L
WO2013138670A1 (en) Yellow fever virus ns5 mutants as flavivirus vaccine candidates
US20220184202A1 (en) A recombinant htlv-1 vaccine
Makadiya Functional characterization of 100K protein of bovine adenovirus type 3
Wang et al. Blocking HSV-1 glycoprotein K binding to signal peptide peptidase reduces virus infectivity in vitro and in vivo
Li et al. Cyclin-dependent kinase regulation of the replication functions of polyomavirus large T antigen
WO2007131182A2 (en) System for high production of natural and personalized interferons
Serrano Role of Spz1 in HPV-mediated carcinogenesis
Ke Innate immune modulation and pathogenic basis for porcine reproductive and respiratory syndrome virus
OA21734A (en) Influenza virus-based isolated recombinant virus.
EA048516B1 (ru) Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа
Khalique Transcriptional control of ICPO and its effect on herpes simplex virus-1 replication
CN120789046A (zh) 桑皮酮h在制备治疗或预防猪流行性腹泻病毒感染的药物的应用
Kim Expression of the non-structural proteins NS3/4A of the hepatitis C virus using a genetically modified vesicular stomatitis virus vector system
Codogno et al. The Herpes Simplex Virus 1 Us11 Protein